Yes, certain antipsychotics can help with depression, but not as a first-line treatment. Four atypical antipsychotics are FDA-approved specifically as add-on therapies for major depressive disorder when an antidepressant alone isn’t working well enough: aripiprazole, quetiapine extended-release, brexpiprazole, and cariprazine. They’re prescribed at much lower doses than what’s used for conditions like schizophrenia, and they work through different brain pathways than traditional antidepressants.
When Antipsychotics Enter the Picture
Antipsychotics aren’t prescribed for depression right away. They’re brought in when you’ve already tried at least one or two antidepressants without getting adequate relief. This situation, often called treatment-resistant depression, affects a significant portion of people with major depressive disorder. Rather than replacing your antidepressant, the antipsychotic is added on top of it, which is why clinicians refer to this as “augmentation therapy.”
The logic is straightforward: if your antidepressant gets you partway there but you’re still struggling with low mood, poor motivation, or other lingering symptoms, a low-dose antipsychotic can target brain chemistry your antidepressant isn’t reaching. Systematic reviews comparing this approach to other augmentation strategies, like adding lithium, have found that both options are likely to be beneficial for treatment-resistant depression.
How They Work Differently Than Antidepressants
Standard antidepressants primarily increase the availability of serotonin, norepinephrine, or both. Atypical antipsychotics cast a wider net. At low doses, they influence dopamine receptors (releasing from them quickly rather than blocking them tightly), dial down stress hormone levels, and interact with multiple serotonin receptor subtypes that standard antidepressants don’t touch. They also appear to boost levels of a protein called BDNF that supports the growth and survival of brain cells, a process thought to be impaired in depression.
This broader mechanism explains why they can help when antidepressants alone fall short. Your depression may involve neurochemical imbalances that a single-target medication can’t fully correct. The combination covers more ground.
How Well They Actually Work
The improvements are real but modest. In a clinical trial of older adults with treatment-resistant depression, adding aripiprazole to an existing antidepressant led to remission (essentially, symptoms dropping to minimal levels) in 44% of participants, compared to 29% on placebo. That means for roughly every seven people who try it, one additional person achieves remission who wouldn’t have otherwise. Depression scores on a standard rating scale dropped about 7.5 points over 12 weeks with aripiprazole, versus 5 points with placebo.
Brexpiprazole shows a similar pattern. In patients who had minimal response to their antidepressant, adding brexpiprazole reduced depression scores by 8.8 points over six weeks, compared to 6.3 points with placebo. That’s a meaningful difference, though not a dramatic one. Patients who already had a partial response to their antidepressant saw a smaller additional benefit from brexpiprazole, with a score difference of about 1.5 points over placebo.
These numbers illustrate an important reality: antipsychotic augmentation helps a meaningful number of people, but it’s not a guaranteed fix. You’re more likely to benefit if your antidepressant has barely moved the needle than if it’s already gotten you most of the way there.
Lower Doses Than You Might Expect
The doses used for depression are substantially lower than those used for psychotic conditions. Quetiapine provides a clear example. For schizophrenia, the typical range is 150 to 750 mg daily. For depression augmentation, the range drops to 50 to 300 mg daily. This matters because many side effects are dose-dependent: a lower dose means a lower risk of the more serious effects associated with antipsychotics at full strength.
What to Expect With Timing
Clinical trials typically measure outcomes over 4 to 12 weeks, with eight weeks being a common benchmark. You shouldn’t expect overnight results. Some people notice subtle shifts in mood or motivation within the first few weeks, but the full effect often takes longer to emerge. Quality-of-life improvements, like feeling more engaged at work or in relationships, tend to lag behind the measurable drop in depressive symptoms.
Side Effects Worth Knowing About
Even at lower doses, antipsychotics carry side effects that antidepressants typically don’t. Weight gain is the most common concern, though the risk varies by medication. Aripiprazole and brexpiprazole have a low propensity for weight gain, while quetiapine carries a moderate risk. For comparison, older antipsychotics like olanzapine and clozapine are associated with the most significant weight increases along with elevations in cholesterol and blood sugar.
Sedation is another frequent side effect, particularly with quetiapine, which is why it’s often taken at bedtime. Some people find this helpful if insomnia is part of their depression; others find the next-day grogginess difficult to manage. Restlessness (a jittery, can’t-sit-still feeling) is more common with aripiprazole and brexpiprazole.
Metabolic Monitoring While on Treatment
Because antipsychotics can affect metabolism even at low doses, guidelines from the American Diabetes Association and American Psychiatric Association recommend regular monitoring for anyone taking these medications. During the first year, this includes checking your weight and BMI at least seven times, blood pressure at least three times, fasting blood sugar at least three times, and cholesterol levels at least twice. Your provider should also take baseline measurements before you start the medication so changes can be tracked over time.
This monitoring schedule might sound intensive, but it reflects a real concern. Metabolic changes can creep up gradually, and catching them early gives you and your provider the chance to adjust your treatment plan before they become serious health issues. If you’re prescribed an antipsychotic for depression and your provider doesn’t mention metabolic monitoring, it’s worth asking about it.